undamentalytics Newsletter
Sign in

Nurix Therapeutics, Inc. income statement

In fiscal 2025, Nurix Therapeutics, Inc. reported revenue of $84.0m, up 54.0% on the year before, operating income of −$286m (a -340.2% margin) and net income of −$264m, or −$3.05 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Nov 20192020Nov 20202021Nov 20212022Nov 20222023Nov 20232024Nov 20242025Nov 2025LTMAug 2026
Revenue31183039775584702
Research and development4566116184189222317334
General and administrative816313843465378
Operating income−22−65−118−184−155−213−286290
Income before tax−21−64−117−180−144−193−264—
Income tax0−210000113
Net income−22−43−117−180−144−194−264295
Diluted EPS−$1.32−$2.76−$2.73−$3.71−$2.65−$2.88−$3.05$2.73
Diluted shares (average)16m16m43m49m54m67m87m108m
EBITDA−20−63−115−179−148−204−277298

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NRIX vs RAREARWR vs NRIXMIRM vs NRIX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Nurix Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nurix Therapeutics, Inc.